Clinical Trial

Phase 2 Study to Assess the Safety and Efficacy of Subcutaneous Blinatumomab in Patients With Measurable Residual Disease Positive B-cell Acute Lymphoblastic Leukemia

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To find out if giving blinatumomab as injections under the skin can help to control MRD and keep the disease from coming back in participants with B-cell ALL.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-09-23; most recent amendment 2026-04-29.
Trial Details
NCT Number NCT07192237
Lead Sponsor M.D. Anderson Cancer Center
Collaborators: Amgen
Conditions Phase 2 Study, Blinatumomab, Acute Lymphoblastic Leukemia
Enrollment 40 participants
Start Date 2026-09-27
Primary Completion 2030-10-12 (estimated)
Study Completion 2032-10-12 (estimated)
Updated on ClinicalTrials.gov 2026-08-12